• Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=11304728; PubMed=14518029).
  

PubMed=9095173; DOI=10.1038/nm0497-402
Klein K.A., Reiter R.E., Redula J., Moradi H., Zhu X.-L., Brothman A.R., Lamb D.J., Marcelli M., Belldegrun A.S., Witte O.N., Sawyers C.L.
Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice.
Nat. Med. 3:402-408(1997)

PubMed=10861745; DOI=10.1002/1097-0045(20000601)43:4<263::AID-PROS5>3.0.CO;2-I
van Weerden W.M., Romijn J.C.
Use of nude mouse xenograft models in prostate cancer research.
Prostate 43:263-271(2000)

PubMed=11304728; DOI=10.1002/pros.1045
van Bokhoven A., Varella-Garcia M., Korch C.T., Hessels D., Miller G.J.
Widely used prostate carcinoma cell lines share common origins.
Prostate 47:36-51(2001)

Patent=US6365797
Sawyers C.L., Klein K.A., Witte O.N., Reiter R.E.
Mice models of human prostate cancer progression.
Patent number US6365797, 02-Apr-2002

PubMed=12725112; DOI=10.1385/1-59259-372-0:21
Russell P.J., Kingsley E.A.
Human prostate cancer cell lines.
Methods Mol. Med. 81:21-39(2003)

PubMed=14518029; DOI=10.1002/pros.10290
van Bokhoven A., Varella-Garcia M., Korch C.T., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.
Molecular characterization of human prostate carcinoma cell lines.
Prostate 57:205-225(2003)

PubMed=14518030; DOI=10.1002/pros.10291
van Bokhoven A., Caires A., Di Maria M., Schulte A.P., Lucia M.S., Nordeen S.K., Miller G.J., Varella-Garcia M.
Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines.
Prostate 57:226-244(2003)

CLPUB00698
van Bokhoven A.
Models for prostate cancer. Molecular characterization and critical appraisal of human prostate carcinoma cell lines.
Thesis PhD (2004); Katholieke Universiteit Nijmegen; Nijmegen; Netherlands

PubMed=15486987; DOI=10.1002/pros.20158
Zhao H.-J., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R., Brooks J.D.
Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.
Prostate 63:187-197(2005)

PubMed=15643173; DOI=10.1097/01.ju.0000149989.01263.dc
Sobel R.E., Sadar M.D.
Cell lines used in prostate cancer research: a compendium of old and new lines -- part 2.
J. Urol. 173:360-372(2005)

PubMed=21698104; DOI=10.1371/journal.pone.0020874; PMCID=PMC3117837
Sfanos K.S., Aloia A.L., Hicks J.L., Esopi D.M., Steranka J.P., Shao W., Sanchez-Martinez S., Yegnasubramanian S., Burns K.H., Rein A., De Marzo A.M.
Identification of replication competent murine gammaretroviruses in commonly used prostate cancer cell lines.
PLoS ONE 6:E20874-E20874(2011)

PubMed=21750403; DOI=10.4161/cbt.12.7.15955; PMCID=PMC3218386
Zhang Y.-A., Maitra A., Hsieh J.-T., Rudin C.M., Peacock C.D., Karikari C., Brekken R.A., Stastny V.A., Gao B.-N., Girard L., Wistuba I.I., Frenkel E.P., Minna J.D., Gazdar A.F.
Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts.
Cancer Biol. Ther. 12:617-628(2011)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=28145883; DOI=10.18632/oncotarget.14850; PMCID=PMC5386661
Nouri M., Caradec J., Lubik A.A., Li N., Hollier B.G., Takhar M., Altimirano-Dimas M., Chen M.-Q., Roshan-Moniri M., Butler M., Lehman M., Bishop J.L., Truong S., Huang S.-C., Cochrane D.R., Cox M., Collins C., Gleave M.E., Erho N., Alshalafa M., Davicioni E., Nelson C., Gregory-Evans C.Y., Karnes R.J., Jenkins R.B., Klein E.A., Buttyan R.
Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.
Oncotarget 8:18949-18967(2017)

PubMed=29739788; DOI=10.1158/1078-0432.CCR-18-0410; PMCID=PMC6125187
de Leeuw R., McNair C., Schiewer M.J., Poudel-Neupane N., Brand L.J., Augello M.A., Li Z., Cheng L.C., Yoshida A., Courtney S.M., Hazard E.S., Hardiman G., Hussain M.H., Diehl J.A., Drake J.M., Kelly W.K., Knudsen K.E.
MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer.
Clin. Cancer Res. 24:4201-4214(2018)

PubMed=34402095; DOI=10.1002/pros.24210; PMCID=PMC8460612
Haffner M.C., Bhamidipati A., Tsai H.K., Esopi D.M., Vaghasia A.M., Low J.-Y., Patel R.A., Guner G., Pham M.-T., Castagna N., Hicks J.L., Wyhs N., Aebersold R., De Marzo A.M., Nelson W.G., Guo T.-N., Yegnasubramanian S.
Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer.
Prostate 81:1159-1171(2021)